CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade AbCellera Biologics Inc. - ABCL CFD

5.02
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 5.02
Open* 5
1-Year Change* -40.41%
Day's Range* 5 - 5.23
52 wk Range 3.87-11.38
Average Volume (10 days) 1.50M
Average Volume (3 months) 30.87M
Market Cap 1.51B
P/E Ratio -100.00K
Shares Outstanding 290.17M
Revenue 50.39M
EPS -0.45
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 5.02 -0.04 -0.79% 5.06 5.23 4.95
Feb 29, 2024 5.02 -0.11 -2.14% 5.13 5.13 4.93
Feb 28, 2024 5.05 0.08 1.61% 4.97 5.17 4.83
Feb 27, 2024 5.08 0.18 3.67% 4.90 5.18 4.90
Feb 26, 2024 4.91 0.16 3.37% 4.75 4.93 4.75
Feb 23, 2024 4.85 -0.01 -0.21% 4.86 5.06 4.79
Feb 22, 2024 4.83 -0.14 -2.82% 4.97 4.97 4.79
Feb 21, 2024 4.78 -0.40 -7.72% 5.18 5.18 4.63
Feb 20, 2024 5.28 -0.05 -0.94% 5.33 5.43 5.20
Feb 16, 2024 5.32 0.17 3.30% 5.15 5.38 5.05
Feb 15, 2024 5.26 0.03 0.57% 5.23 5.38 5.15
Feb 14, 2024 5.20 0.06 1.17% 5.14 5.26 5.12
Feb 13, 2024 5.09 0.00 0.00% 5.09 5.23 5.01
Feb 12, 2024 5.42 0.36 7.11% 5.06 5.43 5.02
Feb 9, 2024 5.09 0.11 2.21% 4.98 5.12 4.97
Feb 8, 2024 4.99 0.15 3.10% 4.84 5.05 4.82
Feb 7, 2024 4.88 -0.21 -4.13% 5.09 5.14 4.86
Feb 6, 2024 5.15 0.33 6.85% 4.82 5.15 4.81
Feb 5, 2024 4.92 0.02 0.41% 4.90 4.92 4.75
Feb 2, 2024 4.98 -0.07 -1.39% 5.05 5.05 4.80

AbCellera Biologics Inc. Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

19:50

Country

US

Event

Abcellera Biologics Inc at TD Cowen Health Care Conference
Abcellera Biologics Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Abcellera Biologics Inc Earnings Release
Q1 2024 Abcellera Biologics Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

16:00

Country

US

Event

Abcellera Biologics Inc Annual Shareholders Meeting
Abcellera Biologics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 485.424 375.203 233.155 11.6115 8.83056
Revenue 485.424 375.203 233.155 11.6115 8.83056
Total Operating Expense 268.913 170.79 80.824 15.7285 9.58317
Selling/General/Admin. Expenses, Total 66.755 48.761 15.752 4.01153 2.86219
Research & Development 107.879 62.062 29.393 10.1129 5.80252
Depreciation / Amortization 27.843 14.451 4.836 1.60408 0.91846
Operating Income 216.511 204.413 152.331 -4.11701 -0.75261
Interest Income (Expense), Net Non-Operating 12.034 -2.75 -2.818 0.13181 -0.5325
Other, Net 10.554 17.486 8.32 1.7745 1.59397
Net Income Before Taxes 239.099 219.149 157.833 -2.2107 0.30885
Net Income After Taxes 158.519 153.464 118.918 -2.2107 0.30885
Net Income Before Extra. Items 158.519 153.464 118.918 -2.2107 0.30885
Net Income 158.519 153.464 118.918 -2.2107 0.30885
Total Adjustments to Net Income 0 -0.01695
Income Available to Common Excl. Extra. Items 158.519 153.464 118.918 -2.2107 0.29191
Income Available to Common Incl. Extra. Items 158.519 153.464 118.918 -2.2107 0.29191
Diluted Net Income 158.519 153.464 118.918 -2.2107 0.29191
Diluted Weighted Average Shares 314.827 318.294 269.498 265.565 265.565
Diluted EPS Excluding Extraordinary Items 0.50351 0.48215 0.44126 -0.00832 0.0011
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS 0.50351 0.48215 0.4516 -0.00832 0.0011
Unusual Expense (Income) 3.7
Other Operating Expenses, Total 66.436 45.516 27.143
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 10.056 12.192 21.545 101.383 45.917
Revenue 10.056 12.192 21.545 101.383 45.917
Total Operating Expense 61.445 77.066 59.323 63.648 54.313
Selling/General/Admin. Expenses, Total 19.362 18.905 15.706 16.881 17.532
Research & Development 36.473 52.647 28.245 26.582 26.685
Depreciation / Amortization 5.61 5.514 13.818 5.15 4.886
Other Operating Expenses, Total 0 0 1.554 15.035 5.21
Operating Income -51.389 -64.874 -37.778 37.735 -8.396
Interest Income (Expense), Net Non-Operating 10.779 9.759 12.034
Other, Net 2.606 6.967 -5.668 8.852 1.51
Net Income Before Taxes -38.004 -48.148 -31.412 46.587 -6.886
Net Income After Taxes -30.528 -40.11 -29.893 26.624 -6.785
Net Income Before Extra. Items -30.528 -40.11 -29.893 26.624 -6.785
Net Income -30.528 -40.11 -29.893 26.624 -6.785
Income Available to Common Excl. Extra. Items -30.528 -40.11 -29.893 26.624 -6.785
Income Available to Common Incl. Extra. Items -30.528 -40.11 -29.893 26.624 -6.785
Diluted Net Income -30.528 -40.11 -29.893 26.624 -6.785
Diluted Weighted Average Shares 288.906 287.767 286.308 315.818 284.687
Diluted EPS Excluding Extraordinary Items -0.10567 -0.13938 -0.10441 0.0843 -0.02383
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.10567 -0.13938 -0.10441 0.0843 -0.02383
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1025.49 929.8 813.325 12.6403 15.1622
Cash and Short Term Investments 886.485 722.977 595.019 9.67689 11.0399
Cash & Equivalents 386.535 476.142 594.116 7.55292 10.4443
Short Term Investments 499.95 246.835 0.903 2.12397 0.59558
Total Receivables, Net 103.41 174.858 212.336 2.25386 3.57203
Accounts Receivable - Trade, Net 38.593 160.576 212.336 1.15256 0.80888
Prepaid Expenses 9.064 5.293 0.70959 0.55034
Total Assets 1540.91 1318.57 1005.54 23.4881 21.4922
Property/Plant/Equipment, Total - Net 217.255 111.616 17.923 8.47994 6.32994
Property/Plant/Equipment, Total - Gross 235.73 121.442 23.509 11.6369 7.88282
Accumulated Depreciation, Total -18.475 -9.826 -5.586 -3.15696 -1.55288
Note Receivable - Long Term 0 1.78302 0
Other Long Term Assets, Total 46.331 30.642 8.388 0.58478 0
Total Current Liabilities 118.32 120.676 103.49 7.89486 6.43338
Payable/Accrued 14.828 14.924 7.13 1.64337 1.51822
Accrued Expenses 12.037 3.652 0.675 0.41914 0
Notes Payable/Short Term Debt 0 0 0 0.38725 0
Current Port. of LT Debt/Capital Leases 0.19 2.07973 2.53135
Other Current Liabilities, Total 91.455 102.1 95.495 3.36537 2.38381
Total Liabilities 307.63 292.836 175.028 13.2359 9.88297
Total Long Term Debt 0 0 2.198 1.36314 0.91122
Long Term Debt 2.198 1.36314 0.91122
Other Liabilities, Total 156.132 134.79 43.179 3.97792 2.53837
Total Equity 1233.28 1025.73 830.508 10.2521 11.6092
Preferred Stock - Non Redeemable, Net 0 7.54585 7.55701
Common Stock 734.365 722.43 710.387 5.12175 5.07369
Additional Paid-In Capital 74.118 35.357 5.919 2.30018 1.48344
Retained Earnings (Accumulated Deficit) 426.185 267.666 114.202 -4.71563 -2.50494
Total Liabilities & Shareholders’ Equity 1540.91 1318.57 1005.54 23.4881 21.4922
Total Common Shares Outstanding 286.852 283.257 269.498 265.565 265.565
Other Current Assets, Total 25 25 5.97
Goodwill, Net 47.806 47.806 31.5
Intangibles, Net 131.502 148.392 115.153
Long Term Investments 72.522 50.313 19.247
Deferred Income Tax 33.178 37.37 26.161
Total Inventory 1.532 1.672
Other Equity, Total -1.391 0.28
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 919.518 930.735 940.653 1025.49 1045.67
Cash and Short Term Investments 785.84 795.694 796.495 886.485 868.206
Cash & Equivalents 172.422 179.747 193.017 386.535 371.973
Total Receivables, Net 75.483 86.233 99.569 103.41 105.964
Accounts Receivable - Trade, Net 37.446 45.678 20.003 38.593 105.964
Total Inventory 1.194 1.447 1.447 1.532
Prepaid Expenses 32.001 22.361 18.142 9.064
Total Assets 1512.19 1537.17 1497.92 1540.91 1552.41
Property/Plant/Equipment, Total - Net 277.209 259.64 233.187 217.255 200.602
Property/Plant/Equipment, Total - Gross 304.239 283.847 254.52 235.73 216.339
Accumulated Depreciation, Total -27.03 -24.207 -21.333 -18.475 -15.737
Goodwill, Net 47.806 47.806 47.806 47.806 47.806
Intangibles, Net 124.076 126.747 128.845 131.502 142.548
Long Term Investments 62.887 58.792 57.583 72.522 66.718
Other Long Term Assets, Total 80.694 113.446 89.845 46.331 49.066
Total Current Liabilities 110.239 118.905 89.591 118.32 106.052
Payable/Accrued 17.432 21.025 17.569 14.828 9.319
Accrued Expenses 11.923 9.812 7.66 12.037 28.084
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 80.884 88.068 64.362 91.455 68.649
Total Liabilities 329.415 342.339 289.419 307.63 302.237
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Deferred Income Tax 33.178 33.178 33.426 33.178 34.143
Other Liabilities, Total 185.998 190.256 166.402 156.132 162.042
Total Equity 1182.78 1194.83 1208.5 1233.28 1250.17
Common Stock 747.914 744.756 742.816 734.365 730.427
Additional Paid-In Capital 109.384 96.423 81.63 74.118 64.384
Retained Earnings (Accumulated Deficit) 326.937 355.547 386.075 426.185 456.078
Total Liabilities & Shareholders’ Equity 1512.19 1537.17 1497.92 1540.91 1552.41
Total Common Shares Outstanding 289.778 289.189 288.427 286.852 285.762
Other Equity, Total -1.46 -1.899 -2.021 -1.391 -0.717
Other Current Assets, Total 25 25 25 25 71.499
Short Term Investments 613.418 615.947 603.478 499.95 496.233
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 158.519 153.464 118.918 -2.2107 0.30885
Cash From Operating Activities 277.36 244.584 22.69 2.69372 3.56564
Cash From Operating Activities 8.953 4.403 2.317 1.60408 0.91846
Non-Cash Items 63.287 37.001 13.539 1.32723 0.42774
Changes in Working Capital 29.825 41.672 -116.701 1.9731 1.91059
Cash From Investing Activities -352.625 -332.247 -119.78 -5.77991 -5.30707
Capital Expenditures -72.66 -58.452 -14.673 -3.99689 -5.30707
Other Investing Cash Flow Items, Total -279.965 -273.795 -105.107 -1.78302 0
Cash From Financing Activities -1.628 -3.886 683.653 0.19483 12.1857
Issuance (Retirement) of Stock, Net 2.755 4.615 598.502 0.01416 10.2056
Issuance (Retirement) of Debt, Net -0.323 -0.951 85.151 0.18067 1.98015
Net Change in Cash -86.492 -92.974 586.563 -2.89137 10.4443
Amortization 18.89 10.062 2.519
Deferred Taxes -2.114 -2.018 2.098
Financing Cash Flow Items -4.06 -7.55
Foreign Exchange Effects -9.599 -1.425
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -40.11 158.519 188.412 161.788 168.573
Cash From Operating Activities -44.063 277.36 246.448 373.234 100.219
Cash From Operating Activities 2.858 8.953 6.212 3.681 1.391
Amortization 2.656 18.89 7.844 5.213 2.606
Deferred Taxes -2.114
Non-Cash Items 13.446 63.287 43.148 26.226 12.675
Changes in Working Capital -22.913 29.825 0.832 176.326 -85.026
Cash From Investing Activities -149.609 -352.625 -335.562 -53.568 -26.371
Capital Expenditures -14.984 -72.66 -60.33 -45.817 -14.495
Other Investing Cash Flow Items, Total -134.625 -279.965 -275.232 -7.751 -11.876
Cash From Financing Activities -0.458 -1.628 -1.977 -1.958 -3.131
Financing Cash Flow Items -0.948 -4.06 -4.06 -4.06 -5
Issuance (Retirement) of Stock, Net 0.49 2.755 2.406 2.175 1.941
Issuance (Retirement) of Debt, Net -0.323 -0.323 -0.073 -0.072
Foreign Exchange Effects -0.213 -9.599 -9.963 -1.411 -0.204
Net Change in Cash -194.343 -86.492 -101.054 316.297 70.513
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Thermopylae Holdings Ltd Corporation 19.3576 56012493 153000 2023-05-26 LOW
Baillie Gifford & Co. Investment Advisor 9.1115 26364751 6535100 2023-06-30 LOW
Baker Bros. Advisors LP Hedge Fund 5.6851 16450180 6000000 2023-06-30 LOW
Thiel (Peter A. J.D.) Individual Investor 4.9629 14360427 0 2023-04-24 LOW
Voya Investment Management LLC Investment Advisor/Hedge Fund 3.6717 10624185 -213840 2023-06-30 LOW
Lecault (Veronique) Individual Investor 3.2936 9530340 20000 2023-09-12 LOW
Capital World Investors Investment Advisor 2.9101 8420493 -907000 2023-06-30 LOW
Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.5809 4574523 -33574 2023-06-30 LOW
Baillie Gifford Overseas Ltd. Investment Advisor 1.5726 4550522 0 2023-08-31 LOW
OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.4449 4180768 0 2023-06-30 LOW
Founders Fund Venture Capital 1.4448 4180547 0 2023-06-30 LOW
ArrowMark Colorado Holdings, LLC Investment Advisor/Hedge Fund 1.4187 4105095 4105095 2023-06-30 MED
Lazard Asset Management, L.L.C. Investment Advisor/Hedge Fund 1.1319 3275301 32102 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.1293 3267618 2060920 2023-06-30 HIGH
Federated Hermes International Investment Advisor/Hedge Fund 1.1246 3254000 446935 2023-06-30 LOW
Prosight Capital Hedge Fund 0.8813 2550000 1796472 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 0.8766 2536603 -274900 2023-06-30 HIGH
Casdin Capital, LLC Hedge Fund 0.8709 2520000 0 2023-06-30 LOW
Citadel Advisors LLC Hedge Fund 0.7582 2193770 719890 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6975 2018226 -9039634 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AbCellera Biologics Inc. Company profile

AbCellera Biologics Inc. (ABCL) is a Canadian biotechnology company that develops antibody discovery platforms. Its full-stack, AI-powered drug discovery platform searches and analyses the database of natural immune systems to find antibodies that can be used by its partners to develop into drugs. 

ABCL was established in 2012 as a spin-off from the University of British Columbia (UBC), where Dr Carl Hansen, the company’s founding CEO, was a faculty member from 2005 to 2019.

The Vancouver-based company has collaborations with drug developers ranging from large cap pharmaceuticals to small biotechnology firms. As of the earnings date of 31 December 2021, the company had 156 discovery programmes either completed, in progress or under contract with 36 partners.

As a recent example, AbCellera Biologics teamed with pharma giant Eli Lilly (LLY) to co-develop two antibody therapeutics to treat and prevent Covid-19 utilising ABCL’s technological stack.

Some of the pharmaceutical companies that partnered with ABCL in the past two years include Everest Medicines for oncology or cancer; Kodiak Sciences (KOD) for partnership in eye care, Novarties (NVS), and Gilead Sciences (GILD) for infectious disease. 

AbCellera Biologics was listed as a public company and began trading on the NASDAQ stock exchnage under the ticker symbol ‘ABCL’ in December 2020 through an initial public offering (IPO). ABCL’s stock price was set at $20.

You can follow the ups and downs of the ABCL’s stock price at Capital.com. Also, stay on top of the latest AbCellera Biologics’ stock price developments with our live ABCL stock chart.

Industry: Biotechnology & Medical Research (NEC)

2215 Yukon Street
VANCOUVER
BRITISH COLUMBIA V5Y 0A1
CA

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Oil - Crude

79.62 Price
+0.160% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,080.74 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.30

XRP/USD

0.64 Price
-0.780% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

US100

18,317.10 Price
+0.180% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading